Literature DB >> 30221153

Effectiveness of additional resection of the invasive cancer-positive proximal bile duct margin in cases of hilar cholangiocarcinoma.

Wen-Jie Ma1, Zhen-Ru Wu2, Anuj Shrestha1,3, Qin Yang1, Hai-Jie Hu1, Jun-Ke Wang1, Fei Liu1, Rong-Xing Zhou1, Quan-Sheng Li1, Fu-Yu Li1.   

Abstract

BACKGROUND: The survival benefits of additional resection of the positive proximal ductal margin (PM) in hilar cholangiocarcinoma (HCCA) remains controversial. This retrospective study investigated the effectiveness of additional resection of the invasive cancer PM under different levels of preoperative carbohydrate antigen 19-9 (CA19-9).
METHODS: Patients who underwent hepatectomy for HCCA from 2000 to 2017 were analyzed. Surgical variables, resection margin status, length of the PM (LPM), prognostic factors, and survival were evaluated.
RESULTS: A total of 228 patients were enrolled: 175 PM(-) without additional resection patients (group A), 21 PM(-) after additional resection (group B), 16 PM(+) without additional resection (group C), and 16 PM(+) after additional resection (group D). The median survival of group B (20.99 months) was similar to that of group A (23.00 months; P=0.16), and both were significantly better than those of group C (11.60 months) and D (9.50 months), especially when preoperative CA19-9>150 U/mL (P<0.05). The survival of patients with an LPM >10 mm was significantly better compared with those with an LPM ≤10 mm, especially when preoperative CA19-9 was >150 U/mL (P<0.05). Only in the LPM >10 mm group, the survival of group B was comparable with that of group A (P>0.05).
CONCLUSIONS: HCCA patients could get a survival benefit from a negative PM resulting from additional resection. Survival could be comparable with that of negative PM without additional resection among HCCA patients. An LPM >10 mm is possibly more associated with better survival compared with whether additional resection of the positive PM is performed under different levels of preoperative CA19-9.

Entities:  

Keywords:  Klatskin tumor; antigens, neoplasm; bile ducts; carbohydrate antigen 19-9 (CA19-9); margins of excision

Year:  2018        PMID: 30221153      PMCID: PMC6131255          DOI: 10.21037/hbsn.2018.03.14

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  37 in total

1.  High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer.

Authors:  A Ra Choi; Jun Chul Park; Jie-Hyun Kim; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee; Jae Bock Chung
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

2.  Clinical value of additional resection of a margin-positive proximal bile duct in hilar cholangiocarcinoma.

Authors:  Yuji Shingu; Tomoki Ebata; Hideki Nishio; Tsuyoshi Igami; Yoshie Shimoyama; Masato Nagino
Journal:  Surgery       Date:  2009-09-20       Impact factor: 3.982

3.  Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.

Authors:  H Narimatsu; H Iwasaki; F Nakayama; Y Ikehara; T Kudo; S Nishihara; K Sugano; H Okura; S Fujita; S Hirohashi
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

4.  Clinicopathologic studies on perineural invasion of bile duct carcinoma.

Authors:  M R Bhuiya; Y Nimura; J Kamiya; S Kondo; S Fukata; N Hayakawa; S Shionoya
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

5.  Pathological appraisal of lines of resection for bile duct carcinoma.

Authors:  T Ebata; H Watanabe; Y Ajioka; K Oda; Y Nimura
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

6.  A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.

Authors:  H J Kim; M H Kim; S J Myung; B C Lim; E T Park; K S Yoo; D W Seo; S K Lee; Y I Min
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

7.  Surgical resection for hilar cholangiocarcinoma: experience improves resectability.

Authors:  Robert M Cannon; Guy Brock; Joseph F Buell
Journal:  HPB (Oxford)       Date:  2011-12-12       Impact factor: 3.647

Review 8.  Hilar cholangiocarcinoma: current management.

Authors:  Fumito Ito; Clifford S Cho; Layton F Rikkers; Sharon M Weber
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

9.  Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.

Authors:  Hai-Jie Hu; Hui Mao; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

10.  Study of the intrahepatic surgical margin of hilar bile duct carcinoma.

Authors:  Yasunaga Okazaki; Tadashi Horimi; Masahito Kotaka; Sojiro Morita; Motohiro Takasaki
Journal:  Hepatogastroenterology       Date:  2002 May-Jun
View more
  2 in total

1.  Does Intraoperative Frozen Section and Revision of Margins Lead to Improved Survival in Patients Undergoing Resection of Perihilar Cholangiocarcinoma? A Systematic Review and Meta-analysis.

Authors:  Tori Lenet; Richard W D Gilbert; Rory Smoot; Ching-Wei D Tzeng; Flavio G Rocha; Lavanya Yohanathan; Sean P Cleary; Guillaume Martel; Kimberly A Bertens
Journal:  Ann Surg Oncol       Date:  2022-06-25       Impact factor: 4.339

2.  MicroRNA‑137 suppresses the proliferation, migration and invasion of cholangiocarcinoma cells by targeting WNT2B.

Authors:  Tengxiang Chen; Shan Lei; Zhirui Zeng; Shutao Pan; Jinjuan Zhang; Yan Xue; Yuanmei Sun; Jinzhi Lan; Su Xu; Dahua Mao; Bing Guo
Journal:  Int J Mol Med       Date:  2020-01-23       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.